Team

Board

Board

Peter McWilliams, Ph.D.

Dr. McWilliams is the CEO of Glycomine. He was previously a Managing Director at Sanderling Ventures where he was responsible for their investment in Actimis Pharmaceuticals and, as its CEO, led the company into the clinic and through to a successful exit via an acquisition by Boehringer Ingelheim. Prior to joining Sanderling, Dr. McWilliams worked at Genentech where, as a Product Manager in Oncology Commercial Development, he managed a pipeline of oncology products in pre-clinical and clinical development including the anti-angiogenesis therapeutic, Avastin®. Prior to that he was an Associate with Booz & Co (now PwC) in San Francisco where he focused on consulting projects for major US and International life science companies. Prior to that he worked for Oxford Molecular, one of the first companies in the field of rational drug design and bio-informatics. Dr. McWilliams received an M.B.A. from Columbia Business School, where he was an R.C. Kopf Fellow and was elected to Beta Gamma Sigma. He received a Ph.D. and M.A. in Chemistry from Princeton University where he received a Hugh Scott Taylor fellowship. He received a B.A. in Natural Sciences from Cambridge University.

Ken Harrison, Ph.D.

Dr. Harrison is a Principal at Novo Ventures (US), Inc. in San Francisco where he has worked since 2015. Dr. Harrison brings experience as a Senior Market Planning Manager at Genentech, where he helped guide strategic decision making for the Ophthalmology and HER2 franchises.  Prior to Genentech, Dr. Harrison worked as a management consultant at L.E.K. Consulting and as the Entrepreneurship Program Manager at QB3/Mission Bay Capital, where he helped create new programs to launch and support life sciences companies in the Bay Area. Dr. Harrison studied cellular lipid storage and metabolism as an A.P. Giannini Foundation Fellow at the J. David Gladstone Institutes, earned a Ph.D. in Pharmacology from Yale University, and has a B.S. in Molecular Biology from Texas Tech University, where he was a Howard Hughes Medical Institute undergraduate research fellow.

Chris Starr, Ph.D.

Dr. Starr has extensive experience in developing and commercializing biologic and small molecule therapeutics in the orphan genetic disease space through six drug approvals and multiple commercial launches. Dr. Starr co-founded was co-founder and Chief Executive Officer of Raptor Pharmaceuticals since its inception in 2006 until 2015. As Chief Executive Officer, Dr. Starr built Raptor from a startup to a 130 person NASDAQ-listed company with one approved product and two Phase 2 programs. Raptor was acquired by Horizon Pharma in 2016 for $800 mil. Prior to starting Raptor, Dr. Starr co-founded BioMarin Pharmaceuticals Inc. in 1997 where he last served as Senior Vice President and Chief Scientific Officer until 2006 responsible for managing a Scientific Operations team of 181 research, process development, manufacturing and quality personnel through the successful development of commercial manufacturing processes for its enzyme replacement products, and supervised the cGMP design, construction and licensing of BioMarin’s proprietary biological manufacturing facility. Dr. Starr was recipient of a National Research Council Associate Award while a post-doc at the National Institutes of Health in Bethesda, MD. Dr. Starr earned a B.S. from Syracuse University and a Ph.D. in Biochemistry and Molecular Biology from the State University of New York Health Science Center.

Tim Mills, Ph.D.

Dr. Mills has over twenty-five years of experience in venture capital, corporate management and biomedical research. Dr. Mills joined Sanderling in 1998 and has had active roles within multiple portfolio companies including Stentor, acquired by Royal Philips Electronics (PHG), CardioNet (BEAT), Taligen Therapeutics, acquired by Alexion (ALXN), Neomend, acquired by C.R. Bard (BCR), Pulsar Vascular, acquired by Johnson & Johnson (JNJ) and Torax Medical, acquired by (JNJ).  Prior to Sanderling, Dr. Mills served as Corporate Vice President of New Business Development and Chief Scientific Officer of Target Therapeutics and before Target, Dr. Mills served as Director of Business Development and Advanced Research & Development in the Interventional Cardiology Division of Baxter Healthcare, now Edwards Life Science (EW). Dr. Mills was previously the Director of the Artificial Heart Program at University of California, Irvine Medical Center and faculty member at University of California, San Francisco. Dr. Mills received his Ph.D. in Bioengineering from University of California, Berkeley & San Francisco School of Medicine. He also received a M.S. in Electrical Engineering & Computer Science from University of California, Berkeley, and a B.S. in Electrical Engineering from University of Colorado, Boulder.